

**From:** Jeffrey Epstein <jeffreyepsteinorg@gmail.com>

**To:** Jeffrey Epstein <jeevacation@gmail.com>, Cecile de Jongh <[REDACTED]>

**Subject:** Fwd: Re - Ovarian Cancer

**Date:** Thu, 21 Jun 2012 15:05:34 +0000

**Attachments:** Autelitano\_et\_al\_2012-JTM.PDF; Interim\_OvPlex-Clinic\_A-Feb\_2012.pdf

---

As a result of my recent Ovarian Cancer article.

----- Forwarded message -----

From: **Nick Gatsios** <[REDACTED]>

Date: Wed, Jun 20, 2012 at 7:52 PM

Subject: Re - Ovarian Cancer

To: jeffreyepsteinorg <[jeffreyepsteinorg@gmail.com](mailto:jeffreyepsteinorg@gmail.com)>

Cc: Rochelle Lade <[REDACTED]>

Dear Jeffery,

I have just read the article circulated via PR Newswire with some interest and I thought that you might find what we have developed of interest. Attached is our latest data manuscript as well as some additional data that suggests OvPlex™ is best in class in diagnosing symptomatic women earlier and discriminating benign mass from tumours.

At present we have our product distributed in the UK, Singapore, Malaysia and Australia and about to launch into India and Spain.

I feel that it would be mutually beneficial to establish a telco to discuss our desire to move the company to the US and drive the FDA path.

I look forward to hearing back from you soon.

Kind Regards

Nick Gatsios

Managing Director

HealthLinx Limited

576 Swan Street

Richmond Vic 3121

p. [REDACTED]

f. [REDACTED]

m. [REDACTED]